Johnson Investment Counsel’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.26M | Sell |
18,789
-7,851
| -29% | -$1.4M | 0.03% | 209 |
|
|
2026
Q1 | $4.6M | Buy |
26,640
+4,105
| +18% | +$761K | 0.04% | 190 |
|
|
2025
Q4 | $4.5M | Sell |
22,535
-1,341
| -6% | -$243K | 0.04% | 175 |
|
|
2025
Q3 | $3.74M | Buy |
23,876
+3,306
| +16% | +$525K | 0.03% | 196 |
|
|
2025
Q2 | $3.12M | Buy |
20,570
+1,045
| +5% | +$139K | 0.03% | 218 |
|
|
2025
Q1 | $2.94M | Sell |
19,525
-417
| -2% | -$69.9K | 0.03% | 223 |
|
|
2024
Q4 | $3.68M | Sell |
19,942
-1,845
| -8% | -$355K | 0.04% | 188 |
|
|
2024
Q3 | $4.29M | Sell |
21,787
-860
| -4% | -$179K | 0.04% | 173 |
|
|
2024
Q2 | $4.68M | Buy |
22,647
+1,966
| +10% | +$445K | 0.05% | 161 |
|
|
2024
Q1 | $5.6M | Sell |
20,681
-1,651
| -7% | -$394K | 0.06% | 152 |
|
|
2023
Q4 | $5.28M | Buy |
22,332
+2,565
| +13% | +$504K | 0.06% | 149 |
|
|
2023
Q3 | $3.87M | Buy |
19,767
+2,650
| +15% | +$544K | 0.05% | 168 |
|
|
2023
Q2 | $3.6M | Sell |
17,117
-265
| -2% | -$52.7K | 0.04% | 171 |
|
|
2023
Q1 | $3.51M | Buy |
17,382
+2,090
| +14% | +$474K | 0.05% | 171 |
|
|
2022
Q4 | $3.33M | Sell |
15,292
-314
| -2% | -$68.6K | 0.05% | 172 |
|
|
2022
Q3 | $3.07M | Sell |
15,606
-236
| -1% | -$50.9K | 0.05% | 171 |
|
|
2022
Q2 | $3.39M | Sell |
15,842
-422
| -3% | -$103K | 0.05% | 163 |
|
|
2022
Q1 | $4.62M | Sell |
16,264
-308
| -2% | -$95K | 0.06% | 156 |
|
|
2021
Q4 | $6.24M | Buy |
16,572
+569
| +4% | +$221K | 0.08% | 134 |
|
|
2021
Q3 | $6.6M | Sell |
16,003
-1,088
| -6% | -$452K | 0.09% | 125 |
|
|
2021
Q2 | $6.32M | Buy |
17,091
+85
| +0.5% | +$28.4K | 0.09% | 125 |
|
|
2021
Q1 | $4.93M | Buy |
17,006
+2,920
| +21% | +$812K | 0.07% | 136 |
|
|
2020
Q4 | $3.52M | Buy |
14,086
+21
| +0.1% | +$5K | 0.06% | 150 |
|
|
2020
Q3 | $3.19M | Sell |
14,065
-1,168
| -8% | -$242K | 0.06% | 151 |
|
|
2020
Q2 | $2.66M | Sell |
15,233
-921
| -6% | -$147K | 0.05% | 159 |
|
|
2020
Q1 | $2.04M | Sell |
16,154
-1,215
| -7% | -$182K | 0.05% | 172 |
|
|
2019
Q4 | $2.65M | Sell |
17,369
-50
| -0.3% | -$6.92K | 0.05% | 177 |
|
|
2019
Q3 | $2.31M | Buy |
17,419
+2,679
| +18% | +$359K | 0.05% | 182 |
|
|
2019
Q2 | $2.09M | Buy |
14,740
+4,705
| +47% | +$638K | 0.04% | 193 |
|
|
2019
Q1 | $1.46M | Hold |
10,035
| – | – | 0.03% | 245 |
|
|
2018
Q4 | $1.14M | Sell |
10,035
-1,855
| -16% | -$232K | 0.03% | 270 |
|
|
2018
Q3 | $1.6M | Buy |
+11,890
| New | +$1.47M | 0.04% | 238 |
|
Other funds holding CRL
AI
Johnson Investment Counsel's CRL Position: Q2 2026 in Review
Johnson Investment Counsel reduced its Charles River Laboratories (CRL) stake by 29% in Q2 2026, selling an estimated $1.4M and leaving 18,789 shares worth $4.26M. The position accounts for 0.03% of the portfolio, ranked #209.
Johnson Investment Counsel first reported a position in CRL in Q3 2018 and has held it in 32 quarters since. The position peaked at $6.6M in Q3 2021. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Johnson Investment Counsel held 18,789 shares of Charles River Laboratories worth $4.26M as of Q2 2026.
- Johnson Investment Counsel sold 7,851 Charles River Laboratories shares in Q2 2026, an estimated $1.4M.
- Charles River Laboratories made up 0.03% of Johnson Investment Counsel's portfolio in Q2 2026, its #209 holding.
- Johnson Investment Counsel first reported a position in Charles River Laboratories in Q3 2018 and has held it in 32 quarters since.
- Johnson Investment Counsel's Charles River Laboratories position peaked at $6.6M in Q3 2021.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.